A study from the Institute of Molecular and Cellular Biology, A*STAR, Singapore; Department of Biochemistry, Yong Loo Lin School of Medicine, National University of Singapore, Singapore and others shows that “..DP103 defines metastatic potential of human breast cancers“
This study was published in the Aug 1, 2014 Journal of Clinical Investigation [I.F >15] by Prof. Tergonakar, Shin and others from the Institute of Molecular and Cellular Biology, A*STAR, Singapore; and Department of Biochemistry, Yong Loo Lin School of Medicine, National University of Singapore.
On the foundation of this interesting finding, Dr L Boominathan, Director-cum-chief Scientist of GBMD, reports here that: Anti-metastasis therapy against breast cancers: Tumor suppressor p53, TAp63 and TAp73 suppress the expression of DP103 via up regulation of their target genes. This study suggests that p53, TAp63 and TAp73, by up regulating their target genes, they may inhibit the activity of NF-κB/MMP9. Thereby, the metastatic behaviour of human breast cancers. Together, this study suggests that pharmacological formulations encompassing “activators of p53, TAp63 and TAp73” may be used to treat human metastatic breast cancers.
Idea Proposed/Formulated by: Dr L Boominathan Ph.D.
Web: http://genomediscovery.org
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
To cite: Boominathan, L., Anti-metastasis therapy against breast cancers: Tumor suppressor p53, TAp63 and TAp73 suppress the expression of DP103 via up regulation of their target genes, Genome-2-Bio-Medicine Discovery center (GBMD), 25/08/2014, 07.23 am., http://genomediscovery.org
Courtesy: When you cite drop us a line at info@genomediscovery.org
* Research cooperation